- Top line results of TELLOMAK Phase 2 trial in mycosis fungoides confirming promising clinical activity of lacutamab
- Two posters on IPH6501, Innate’s second generation ANKET®, for the treatment of relapsed/refractory CD20-expressing B-cell Non-Hodgkin's Lymphoma
- AstraZeneca to present poster on updated results for monalizumab from Phase 2 stage III unresectable NSCLC trial
- Monalizumab SCLC Phase 2 MOZART trial poster
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.